220 related articles for article (PubMed ID: 16126909)
1. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia.
Funasaka T; Yanagawa T; Hogan V; Raz A
FASEB J; 2005 Sep; 19(11):1422-30. PubMed ID: 16126909
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of phosphoglucose isomerase/autocrine motility factor results in mesenchymal-to-epithelial transition of human lung fibrosarcoma cells.
Funasaka T; Hu H; Yanagawa T; Hogan V; Raz A
Cancer Res; 2007 May; 67(9):4236-43. PubMed ID: 17483335
[TBL] [Abstract][Full Text] [Related]
3. Regulation of phosphoglucose isomerase/autocrine motility factor activities by the poly(ADP-ribose) polymerase family-14.
Yanagawa T; Funasaka T; Tsutsumi S; Hu H; Watanabe H; Raz A
Cancer Res; 2007 Sep; 67(18):8682-9. PubMed ID: 17875708
[TBL] [Abstract][Full Text] [Related]
4. Autocrine motility factor signaling enhances pancreatic cancer metastasis.
Tsutsumi S; Yanagawa T; Shimura T; Kuwano H; Raz A
Clin Cancer Res; 2004 Nov; 10(22):7775-84. PubMed ID: 15570012
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of phosphoglucose isomerase/autocrine motility factor activities by protein kinase CK2 phosphorylation.
Yanagawa T; Funasaka T; Tsutsumi S; Raz T; Tanaka N; Raz A
J Biol Chem; 2005 Mar; 280(11):10419-26. PubMed ID: 15637053
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts.
Tsutsumi S; Hogan V; Nabi IR; Raz A
Cancer Res; 2003 Jan; 63(1):242-9. PubMed ID: 12517804
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence.
Funasaka T; Hu H; Hogan V; Raz A
J Biol Chem; 2007 Dec; 282(50):36362-9. PubMed ID: 17925402
[TBL] [Abstract][Full Text] [Related]
8. Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling.
Tsutsumi S; Yanagawa T; Shimura T; Fukumori T; Hogan V; Kuwano H; Raz A
J Biol Chem; 2003 Aug; 278(34):32165-72. PubMed ID: 12783864
[TBL] [Abstract][Full Text] [Related]
9. Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer.
Funasaka T; Hogan V; Raz A
Cancer Res; 2009 Jul; 69(13):5349-56. PubMed ID: 19531650
[TBL] [Abstract][Full Text] [Related]
10. Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis.
Niinaka Y; Harada K; Fujimuro M; Oda M; Haga A; Hosoki M; Uzawa N; Arai N; Yamaguchi S; Yamashiro M; Raz A
Cancer Res; 2010 Nov; 70(22):9483-93. PubMed ID: 20978190
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of phosphoglucose isomerase/autocrine motility factor enhances gensenoside Rh2 pharmacological action on leukemia KG1α cells.
You ZM; Zhao L; Xia J; Wei Q; Liu YM; Liu XY; Chen DL; Li J
Asian Pac J Cancer Prev; 2014; 15(3):1099-104. PubMed ID: 24606425
[TBL] [Abstract][Full Text] [Related]
12. Silencing of phosphoglucose isomerase/autocrine motility factor decreases U87 human glioblastoma cell migration.
Li Y; Wei Z; Dong B; Lian Z; Xu Y
Int J Mol Med; 2016 Apr; 37(4):998-1004. PubMed ID: 26936801
[TBL] [Abstract][Full Text] [Related]
13. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells.
Ahmad A; Aboukameel A; Kong D; Wang Z; Sethi S; Chen W; Sarkar FH; Raz A
Cancer Res; 2011 May; 71(9):3400-9. PubMed ID: 21389093
[TBL] [Abstract][Full Text] [Related]
14. Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.
Kojic LD; Wiseman SM; Ghaidi F; Joshi B; Nedev H; Saragovi HU; Nabi IR
PLoS One; 2008; 3(10):e3597. PubMed ID: 18974847
[TBL] [Abstract][Full Text] [Related]
15. Induction of hepatoma cells migration by phosphoglucose isomerase/autocrine motility factor through the upregulation of matrix metalloproteinase-3.
Yu FL; Liao MH; Lee JW; Shih WL
Biochem Biophys Res Commun; 2004 Jan; 314(1):76-82. PubMed ID: 14715248
[TBL] [Abstract][Full Text] [Related]
16. Suppression of AMF/PGI-mediated tumorigenic activities by ursolic acid in cultured hepatoma cells and in a mouse model.
Shih WL; Yu FL; Chang CD; Liao MH; Wu HY; Lin PY
Mol Carcinog; 2013 Oct; 52(10):800-12. PubMed ID: 22549898
[TBL] [Abstract][Full Text] [Related]
17. Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy.
Yanagawa T; Funasaka T; Tsutsumi S; Watanabe H; Raz A
Endocr Relat Cancer; 2004 Dec; 11(4):749-59. PubMed ID: 15613449
[TBL] [Abstract][Full Text] [Related]
18. Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells.
Zhao Q; Du J; Gu H; Teng X; Zhang Q; Qin H; Liu N
Pancreas; 2007 Mar; 34(2):242-7. PubMed ID: 17312464
[TBL] [Abstract][Full Text] [Related]
19. AMF/PGI-mediated tumorigenesis through MAPK-ERK signaling in endometrial carcinoma.
Li Y; Jia Y; Che Q; Zhou Q; Wang K; Wan XP
Oncotarget; 2015 Sep; 6(28):26373-87. PubMed ID: 26308071
[TBL] [Abstract][Full Text] [Related]
20. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
